Daptomycin-Oxacillin Combinations in Treatment of Experimental Endocarditis Caused by Daptomycin-Nonsusceptible Strains of Methicillin-Resistant Staphylococcus aureus with Evolving Oxacillin Susceptibility (the “Seesaw Effect”)

ABSTRACT In vivo development of daptomycin resistance (DAPr) among Staphylococcus aureus strains, especially methicillin-resistant S. aureus (MRSA) strains, in conjunction with clinical treatment failures, has emerged as a major problem. This has raised the question of DAP-based combination regimens to enhance efficacy against such strains. We studied five recent DAP-susceptible (DAPs)/DAPr clinical MRSA strain pairs obtained from patients who failed DAP monotherapy regimens, as well as one DAPs/DAPr MRSA strain pair in which the resistant strain was generated by in vitro passage in DAP. Of note, we identified a DAP-oxacillin (OX) “seesaw” phenomenon in vitro in which development of DAPr was accompanied by a concomitant fall in OX resistance, as demonstrated by 3- to 4-fold decreases in the OX MIC, a susceptibility shift by population analyses, and enhanced early killing by OX in time-kill assays. In addition, the combination of DAP and OX exerted modest improvement in in vitro bactericidal effects. Using an experimental model of infective endocarditis and two DAPs/DAPr strain pairs, we demonstrated that (i) OX monotherapy was ineffective at clearing DAPr strains from any target tissue in this model (heart valve, kidneys, or spleen) and (ii) DAP-OX combination therapy was highly effective in DAPr strain clearances from these organs. The mechanism(s) of the seesaw effect remains to be defined but does not appear to involve excision of the staphylococcal cassette chromosome mec (SCCmec) that carries mecA.

[1]  J. Gatell,et al.  Daptomycin Is Effective for Treatment of Experimental Endocarditis Due to Methicillin-Resistant and Glycopeptide-Intermediate Staphylococcus epidermidis , 2008, Antimicrobial Agents and Chemotherapy.

[2]  A. Bayer,et al.  Enhanced expression of dltABCD is associated with the development of daptomycin nonsusceptibility in a clinical endocarditis isolate of Staphylococcus aureus. , 2009, The Journal of infectious diseases.

[3]  K. Ko,et al.  Classification of Staphylococcal Cassette Chromosome mec (SCCmec): Guidelines for Reporting Novel SCCmec Elements , 2009, Antimicrobial Agents and Chemotherapy.

[4]  J. Miro,et al.  Addition of Gentamicin or Rifampin Does Not Enhance the Effectiveness of Daptomycin in Treatment of Experimental Endocarditis Due to Methicillin-Resistant Staphylococcus aureus , 2009, Antimicrobial Agents and Chemotherapy.

[5]  B. Diep,et al.  Relationship between Susceptibility to Daptomycin In Vitro and Activity In Vivo in a Rabbit Model of Aortic Valve Endocarditis , 2009, Antimicrobial Agents and Chemotherapy.

[6]  V. Fowler,et al.  Phenotypic and genotypic characteristics of persistent methicillin-resistant Staphylococcus aureus bacteremia in vitro and in an experimental endocarditis model. , 2009, The Journal of infectious diseases.

[7]  A. Cheung,et al.  Role of mgrA and sarA in methicillin-resistant Staphylococcus aureus autolysis and resistance to cell wall-active antibiotics. , 2009, The Journal of infectious diseases.

[8]  C. Nast,et al.  Analysis of Cell Membrane Characteristics of In Vitro-Selected Daptomycin-Resistant Strains of Methicillin-Resistant Staphylococcus aureus , 2008, Antimicrobial Agents and Chemotherapy.

[9]  N. McCallum,et al.  Impact of mecA promoter mutations on mecA expression and beta-lactam resistance levels. , 2008, International journal of medical microbiology : IJMM.

[10]  P. Fey,et al.  Daptomycin non-susceptible meticillin-resistant Staphylococcus aureus USA 300 isolate. , 2008, Journal of medical microbiology.

[11]  J. Miro,et al.  Daptomycin Is Effective in Treatment of Experimental Endocarditis Due to Methicillin-Resistant and Glycopeptide-Intermediate Staphylococcus aureus , 2008, Antimicrobial Agents and Chemotherapy.

[12]  J. Schrenzel,et al.  Failures in Clinical Treatment of Staphylococcus aureus Infection with Daptomycin Are Associated with Alterations in Surface Charge, Membrane Phospholipid Asymmetry, and Drug Binding , 2007, Antimicrobial Agents and Chemotherapy.

[13]  H. Boucher,et al.  Perspectives on Daptomycin resistance, with emphasis on resistance in Staphylococcus aureus. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[14]  G. Kaatz,et al.  Evaluation of daptomycin treatment of Staphylococcus aureus bacterial endocarditis: an in vitro and in vivo simulation using historical and current dosing strategies. , 2007, The Journal of antimicrobial chemotherapy.

[15]  A. Rubio,et al.  Characterization of a Daptomycin-Nonsusceptible Vancomycin-Intermediate Staphylococcus aureus Strain in a Patient with Endocarditis , 2007, Antimicrobial Agents and Chemotherapy.

[16]  G. Archer,et al.  Identification and Phenotypic Characterization of a β-Lactam-Dependent, Methicillin-Resistant Staphylococcus aureus Strain , 2007, Antimicrobial Agents and Chemotherapy.

[17]  G. Eliopoulos,et al.  Daptomycin Nonsusceptibility in Staphylococcus aureus with Reduced Vancomycin Susceptibility Is Independent of Alterations in MprF , 2007, Antimicrobial Agents and Chemotherapy.

[18]  P. Appelbaum,et al.  Activity of Daptomycin Alone and in Combination with Rifampin and Gentamicin against Staphylococcus aureus Assessed by Time-Kill Methodology , 2007, Antimicrobial Agents and Chemotherapy.

[19]  R. Daum,et al.  Community-acquired methicillin-resistant Staphylococcus aureus: the role of Panton–Valentine leukocidin , 2007, Laboratory Investigation.

[20]  A. MacGowan,et al.  Comparative Bactericidal Activities of Daptomycin and Vancomycin against Glycopeptide-Intermediate Staphylococcus aureus (GISA) and Heterogeneous GISA Isolates , 2006, Antimicrobial Agents and Chemotherapy.

[21]  S. Yin,et al.  The VraS/VraR two-component regulatory system required for oxacillin resistance in community-acquired methicillin-resistant Staphylococcus aureus. , 2006, FEMS microbiology letters.

[22]  G. Archer,et al.  Successful Therapy of Experimental Endocarditis Caused by Vancomycin-Resistant Staphylococcus aureus with a Combination of Vancomycin and β-Lactam Antibiotics , 2006, Antimicrobial Agents and Chemotherapy.

[23]  Ronald N. Jones,et al.  Development of decreased susceptibility to daptomycin and vancomycin in a Staphylococcus aureus strain during prolonged therapy. , 2006, The Journal of antimicrobial chemotherapy.

[24]  L. Friedman,et al.  Genetic Changes That Correlate with Reduced Susceptibility to Daptomycin in Staphylococcus aureus , 2006, Antimicrobial Agents and Chemotherapy.

[25]  D. Skiest Treatment Failure Resulting from Resistance of Staphylococcus aureus to Daptomycin , 2006, Journal of Clinical Microbiology.

[26]  D. Snydman,et al.  Evaluation of In Vitro Interaction of Daptomycin with Gentamicin or Beta-lactam Antibiotics Against taphylococcus aureus and Enterococci by FIC Index and Timed-Kill Curves , 2005, Journal of chemotherapy.

[27]  C. Weidenmaier,et al.  DltABCD- and MprF-Mediated Cell Envelope Modifications of Staphylococcus aureus Confer Resistance to Platelet Microbicidal Proteins and Contribute to Virulence in a Rabbit Endocarditis Model , 2005, Infection and Immunity.

[28]  J. Quinn,et al.  Development of Daptomycin Resistance In Vivo in Methicillin-Resistant Staphylococcus aureus , 2005, Journal of Clinical Microbiology.

[29]  Chih-Chien Wang,et al.  Successful Multiresistant Community-Associated Methicillin-Resistant Staphylococcus aureus Lineage from Taipei, Taiwan, That Carries Either the Novel Staphylococcal Chromosome Cassette mec (SCCmec) Type VT or SCCmec Type IV , 2005, Journal of Clinical Microbiology.

[30]  H. de Lencastre,et al.  Partial Excision of the Chromosomal Cassette Containing the Methicillin Resistance Determinant Results in Methicillin-Susceptible Staphylococcus aureus , 2005, Journal of Clinical Microbiology.

[31]  L. Danziger,et al.  Daptomycin: a novel cyclic lipopeptide antimicrobial. , 2005, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[32]  K. Dietz,et al.  Lack of wall teichoic acids in Staphylococcus aureus leads to reduced interactions with endothelial cells and to attenuated virulence in a rabbit model of endocarditis. , 2005, The Journal of infectious diseases.

[33]  F. Tally,et al.  Daptomycin: a lipopeptide antibiotic for the treatment of serious Gram-positive infections. , 2005, The Journal of antimicrobial chemotherapy.

[34]  A. Tomasz,et al.  Penicillin-Binding Protein 2 Is Essential for Expression of High-Level Vancomycin Resistance and Cell Wall Synthesis in Vancomycin- Resistant Staphylococcus aureus Carrying the Enterococcal vanA Gene Complex , 2004, Antimicrobial Agents and Chemotherapy.

[35]  M. Rybak,et al.  Impact of High-Inoculum Staphylococcus aureus on the Activities of Nafcillin, Vancomycin, Linezolid, and Daptomycin, Alone and in Combination with Gentamicin, in an In Vitro Pharmacodynamic Model , 2004, Antimicrobial Agents and Chemotherapy.

[36]  K. Rand,et al.  Synergy of Daptomycin with Oxacillin and Other β-Lactams against Methicillin-Resistant Staphylococcus aureus , 2004, Antimicrobial Agents and Chemotherapy.

[37]  H. Mori,et al.  Two‐component system VraSR positively modulates the regulation of cell‐wall biosynthesis pathway in Staphylococcus aureus , 2003, Molecular microbiology.

[38]  H. Shapiro,et al.  Correlation of Daptomycin Bactericidal Activity and Membrane Depolarization in Staphylococcus aureus , 2003, Antimicrobial Agents and Chemotherapy.

[39]  Susan K. Johnson,et al.  Vancomycin-intermediate Staphylococcus aureus with phenotypic susceptibility to methicillin in a patient with recurrent bacteremia. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[40]  G. Eliopoulos,et al.  Efficacy of Daptomycin in Experimental Endocarditis Due to Methicillin-Resistant Staphylococcusaureus , 2003, Antimicrobial Agents and Chemotherapy.

[41]  A. Tomasz,et al.  Evolution of a Vancomycin-Intermediate Staphylococcus aureus Strain In Vivo: Multiple Changes in the Antibiotic Resistance Phenotypes of a Single Lineage of Methicillin-Resistant S. aureus under the Impact of Antibiotics Administered for Chemotherapy , 2003, Journal of Clinical Microbiology.

[42]  M. Moore,et al.  Vancomycin Treatment Failure Associated with Heterogeneous Vancomycin-Intermediate Staphylococcus aureus in a Patient with Endocarditis and in the Rabbit Model of Endocarditis , 2003, Antimicrobial Agents and Chemotherapy.

[43]  G. Bierbaum,et al.  Morphological and Genetic Differences in Two Isogenic Staphylococcus aureus Strains with Decreased Susceptibilities to Vancomycin , 2003, Antimicrobial Agents and Chemotherapy.

[44]  P. Donnio,et al.  Nine-Year Surveillance of Methicillin-Resistant Staphylococcus aureus in a Hospital Suggests Instability of mecA DNA Region in an Epidemic Strain , 2002, Journal of Clinical Microbiology.

[45]  R. Daum,et al.  Development of vancomycin and lysostaphin resistance in a methicillin-resistant Staphylococcus aureus isolate. , 2001, The Journal of antimicrobial chemotherapy.

[46]  A. Tomasz,et al.  An acquired and a native penicillin-binding protein cooperate in building the cell wall of drug-resistant staphylococci , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[47]  Teruyo Ito,et al.  Structural Comparison of Three Types of Staphylococcal Cassette Chromosome mec Integrated in the Chromosome in Methicillin-Resistant Staphylococcus aureus , 2001, Antimicrobial Agents and Chemotherapy.

[48]  F. Tally,et al.  Development of daptomycin for gram-positive infections. , 2000, Journal of Antimicrobial Chemotherapy.

[49]  A. Tomasz,et al.  Gradual Alterations in Cell Wall Structure and Metabolism in Vancomycin-Resistant Mutants ofStaphylococcus aureus , 1999, Journal of bacteriology.

[50]  G. Archer,et al.  Combinations of Vancomycin and β-Lactams Are Synergistic against Staphylococci with Reduced Susceptibilities to Vancomycin , 1999, Antimicrobial Agents and Chemotherapy.

[51]  A. Bayer,et al.  Comparative Efficacies of Liposomal Amikacin (MiKasome) plus Oxacillin versus Conventional Amikacin plus Oxacillin in Experimental Endocarditis Induced by Staphylococcus aureus: Microbiological and Echocardiographic Analyses , 1999, Antimicrobial Agents and Chemotherapy.

[52]  A. Tomasz,et al.  The development of vancomycin resistance in a patient with methicillin-resistant Staphylococcus aureus infection. , 1999, The New England journal of medicine.

[53]  A. Tomasz,et al.  Inhibition of cell wall turnover and autolysis by vancomycin in a highly vancomycin-resistant mutant of Staphylococcus aureus , 1997, Journal of bacteriology.

[54]  G. Archer,et al.  Role of mecA transcriptional regulation in the phenotypic expression of methicillin resistance in Staphylococcus aureus , 1996, Journal of bacteriology.

[55]  B. Berger-Bächi Expression of resistance to methicillin. , 1994, Trends in microbiology.

[56]  K. Hiramatsu,et al.  Molecular cloning and nucleotide sequence determination of the regulator region of mecA gene in methicillin‐resistant Staphylococcus aureus (MRSA) , 1992, FEBS letters.

[57]  A. Bayer,et al.  Beta-Lactam-beta-lactamase-inhibitor combinations are active in experimental endocarditis caused by beta-lactamase-producing oxacillin-resistant staphylococci , 1991, Antimicrobial Agents and Chemotherapy.

[58]  Lancé,et al.  3-Lactam---Lactamase-Inhibitor Combinations Are Active in Experimental Endocarditis Caused by , B-Lactamase-Producing Oxacillin-Resistant Staphylococci , 2022 .